Molecular Partners AG ADR (MOLN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.92 (-6.67%), Market cap $0.14B, 52-week low–high $3.47 ~ $5.13.
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x co
Financial statements, price targets, institutional (13F) holdings and related news for Molecular Partners AG ADR are updated in real time on BlackAll Trade.
Molecular Partners AG ADR trades at $3.92 (-6.67%). Real-time quotes and charts are available on BlackAll Trade.
Molecular Partners AG ADR has a market cap of about $0.14B.
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pip